ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)

* In January 2026, ADLM conducted a grassroots campaign urging it members write to Congress in support of H.R.5269/S.2761, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, which would create a new, more equitable Medicare clinical laboratory fee schedule.

Client expense: $120,000 · Firm income: —

Matched citations: H.R.5269

* In January 2026, ADLM conducted a grassroots campaign urging it members write to Congress in support of H.R.5269/S.2761, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, which would create a new, more equitable Medicare clinical laboratory fee schedule.

Client expense: $120,000 · Firm income: —

Matched citations: S.2761

* On October 30, ADLM joined with other healthcare groups in writing to House and Senate leaders supporting H.R.5269/S.2761, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, which would create a new, more equitable Medicare clinical laboratory fee schedule. ADLM also conducted a grassroots campaign targeting House and Senate members in support of the legislation.

Client expense: $40,000 · Firm income: —

Matched citations: H.R.5269

* On October 30, ADLM joined with other healthcare groups in writing to House and Senate leaders supporting H.R.5269/S.2761, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, which would create a new, more equitable Medicare clinical laboratory fee schedule. ADLM also conducted a grassroots campaign targeting House and Senate members in support of the legislation.

Client expense: $40,000 · Firm income: —

Matched citations: S.2761

On July 9th, ADLM joined a coalition letter of more than 100 groups in writing to the Senate Health Education Labor & Pensions and House Energy and Commerce committees urging them to protect the integrity of the United States Preventive Services Task Force (USPSTF). On August 29th, ADLM wrote to Rep. Kelly Morrison (D-MN) in support of H.R.4709, the Newborn Screening Saves Lives Reauthorization Act, which would preserve advances in newborn screening programs.

Client expense: $40,000 · Firm income: —

Matched citations: H.R.4709

* On September 26, ADLM wrote to Rep.Richard Hudson (R-NC) in support of his legislation, H.R.5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, which would create a new, more equitable Medicare clinical laboratory fee schedule.

Client expense: $40,000 · Firm income: —

Matched citations: H.R.5269

* On October 30, ADLM released a position statement on direct to consumer testing urging various federal agencies to improve the quality and oversight of such testing and to prosecute labs engaging in misleading or fraudulent practices. * On November 7, ADLM wrote to Rep. Deborah Ross endorsing H.R.9849, the Medical Laboratory Personnel Shortage Relief Act, which would use federal funding to reduce the healthcare shortage in underserved areas. * On November 20, ADLM wrote to President-elect Donald Trump's transition team urging him to withdraw the FDA's May 6, 2024 final rule regulating Laboratory Developed Tests. * On November 21, ADLM joined a coalition letter to President-elect Donald Trump's transition team urging him to withdraw the FDA's May 6, 2024 final rule regulating LDTs. * On December 10, ADLM wrote to the House and Senate Department of Government Efficiency (DOGE) caucuses urging them to support revocation of the May 6, 2024 final rule on LDTs.

Client expense: $60,000 · Firm income: —

Matched citations: H.R.9849

* On April 2, ADLM provided feedback to Senator Bill Cassidy (R-LA) on the need diagnostic testing reform.v * On April 8, ADLM provided survey results to Senator Bill Cassidy (R-LA) illustrating problems with the Food and Drug Administration's October 3, 2023 proposed rule to regulate laboratory developed tests. * On June 24, 2024 ADLM provided additional survey results to Senate HELP and House Energy & Commerce Committee leaders identifying concerns with the May 6, 2024 FDA final rule on LDTs. * ADLM met with House and Senate legislative staff in support of the Saving Access to Laboratory Services Act, H.R.1835 & S.1000, and conducted a grassroots campaign in support of the bill. *ADLM conducted a grassroots campaign in support of congressional action to revoke the May 6, 2024 FDA rule on LDTs.

Client expense: $140,000 · Firm income: —

Matched citations: H.R.1835

* On April 2, ADLM provided feedback to Senator Bill Cassidy (R-LA) on the need diagnostic testing reform.v * On April 8, ADLM provided survey results to Senator Bill Cassidy (R-LA) illustrating problems with the Food and Drug Administration's October 3, 2023 proposed rule to regulate laboratory developed tests. * On June 24, 2024 ADLM provided additional survey results to Senate HELP and House Energy & Commerce Committee leaders identifying concerns with the May 6, 2024 FDA final rule on LDTs. * ADLM met with House and Senate legislative staff in support of the Saving Access to Laboratory Services Act, H.R.1835 & S.1000, and conducted a grassroots campaign in support of the bill. *ADLM conducted a grassroots campaign in support of congressional action to revoke the May 6, 2024 FDA rule on LDTs.

Client expense: $140,000 · Firm income: —

Matched citations: S.1000

AACC/ADLM organized a grassroots letter writing campaign urging its members to write to their members of Congress in support of S.1000/H.R.2377, the Saving Access to Laboratory Services Act (SALSA), which would update the methodology used by the Centers for Medicare and Medicaid Services in setting laboratory fees.

Client expense: $70,000 · Firm income: —

Matched citations: H.R.2377

AACC/ADLM organized a grassroots letter writing campaign urging its members to write to their members of Congress in support of S.1000/H.R.2377, the Saving Access to Laboratory Services Act (SALSA), which would update the methodology used by the Centers for Medicare and Medicaid Services in setting laboratory fees.

Client expense: $70,000 · Firm income: —

Matched citations: S.1000

AACC joined a coalition of healthcare providing in writing to the House and Senate leadership in support of S.1000/H.R.2377, the Saving Access to Laboratory Services Act (SALSA), which would update the methodology used by the Center for Medicare and Medicaid Services in setting laboratory fees. AACC sent a separate letter to Rep. Richard Hudson endorsing SALSA.

Client expense: $170,000 · Firm income: —

Matched citations: H.R.2377

AACC joined a coalition of healthcare providing in writing to the House and Senate leadership in support of S.1000/H.R.2377, the Saving Access to Laboratory Services Act (SALSA), which would update the methodology used by the Center for Medicare and Medicaid Services in setting laboratory fees. AACC sent a separate letter to Rep. Richard Hudson endorsing SALSA.

Client expense: $170,000 · Firm income: —

Matched citations: S.1000

* AACC met with House and Senate staff, conducted grassroots campaigns, and circulated an advocacy video urging legislators not to include the Verifying Accurate Leading-edge IVCT Development (VALID) Act in the Consolidated Appropriations Act, 2023 * AACC signed a joint letter to House and Senate leaders urging them not to include the Verifying Accurate Leading-edge IVCT Development (VALID) Act in the Consolidated Appropriations Act, 2023 * AACC signed a joint letter to House and Senate leaders and conducted a grassroots campaign urging legislators to include S.4449 - Saving Access to Laboratory Services Act in Consolidated Appropriations Act, 2023

Client expense: $160,000 · Firm income: —

Matched citations: S.4449

AACC joined with other healthcare groups in urging legislators to support H.R.8188/S.4449, the Saving Access to Laboratory Services Act, which would update the Medicare payment structure for clinical laboratory service.

Client expense: $90,000 · Firm income: —

Matched citations: H.R.8188

AACC initiated grassroots campaigns and met with congressional staff in opposition to including the Verifying Accurate Leading-edge IVCT Development (VALID) Act in either the Medical Device User Fees package or a continuing resolution to fund the federal government through 2022. AACC joined with other healthcare groups in urging key Senators to support the passage of S.350, the Newborn Screening Saves Lives Reauthorization Act, which would extend for another five years federal newborn screening programs.

Client expense: $90,000 · Firm income: —

Matched citations: S.350

AACC joined with other healthcare groups in urging legislators to support H.R.8188/S.4449, the Saving Access to Laboratory Services Act, which would update the Medicare payment structure for clinical laboratory service.

Client expense: $90,000 · Firm income: —

Matched citations: S.4449

AACC joined with other healthcare groups in writing to the Senate HELP leadership endorsing S.3534, the Tracking Pathogens Act, which would support and enhance existing genomic sequencing and surveillance activities. AACC met with House and Senate staff urging that the Verifying Accurate Leading-edge IVCT Development (VALID) Act not be included in the Medical Device User Fee Amendments V legislative package that will be considered by Congress. AACC provided input to the Senate HELP committee on its draft "Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act," which would rebuild and strengthen our nations public health infrastructure.

Client expense: $80,000 · Firm income: —

Matched citations: S.3534

AACC joined with other healthcare groups in writing to House and Senate leaders seeking a delay in calendar year 2022 spending cuts in Medicare laboratory fees and laboratory requirements as required under the Protecting Access to Medicare Act. AACC joined with other healthcare groups in writing to the CDC requesting that the Clinical Laboratory Improvement Amendments Advisory Committee take up the issue of laboratory developed tests during one of its future public meetings. AACC wrote to the House and Senate sponsors of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act, HR 4128 and S.2209, expressing concerns about the legislation.

Client expense: $80,000 · Firm income: —

Matched citations: HR 4128

AACC joined with other healthcare groups in writing to House and Senate leaders seeking a delay in calendar year 2022 spending cuts in Medicare laboratory fees and laboratory requirements as required under the Protecting Access to Medicare Act. AACC joined with other healthcare groups in writing to the CDC requesting that the Clinical Laboratory Improvement Amendments Advisory Committee take up the issue of laboratory developed tests during one of its future public meetings. AACC wrote to the House and Senate sponsors of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act, HR 4128 and S.2209, expressing concerns about the legislation.

Client expense: $80,000 · Firm income: —

Matched citations: S.2209

AACC met House and Senate staff to express opposition to H.R.4128 & S.2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, which would extend Food and Drug Administration oversight to laboratory developed tests (LDTs). AACC joined with other healthcare groups in supporting S.1666, the Verified Innovative Testing in American Laboratories (VITAL) Act, which would codify the existing regulatory model for overseeing LDTs.

Client expense: $90,000 · Firm income: —

Matched citations: H.R.4128